Trial
NCT03955471
Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Tesaro, Inc.
Collaborators
Gynecologic Oncology Group
Condition
Ovarian Neoplasms
Intervention
Niraparib
Why stopped
The study will not resume based on the results of a planned interim analysis that showed futility
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-09-10